Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin in Advanced NSCLC
NCT00400829Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2006
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate. Started Nov 2006; status: completed.
02
Drugs
eribulin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00400829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00400829.